Drug discovery pioneer on road to becoming ‘self-sustaining’
Manchester-based biotech company C4X Discovery Holdings – a pioneer in the battle against rheumatoid arthritis and Parkinson’s disease – has spent more than £6m on research as it bids to become a “self-sustaining business”.
R&D expenditure in the year to July 31 rose 16% from 2016, reflecting both the increase in drug discovery activity and the continued development of lead drug candidates towards commercialisation, the company said.
During the period the company raised a total of £12m in share placings, leaving ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
